CA209-9KY: Phase II Study of IMRT Re-Irradiation and Concurrent/Adjuvant Nivolumab (Nivo) in Patients With Loco Regionally Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC) - Toxicity and Quality of Life (QoL) Results

N F Saba,S Wong, W A Stokes, M Rupji,Y Liu, S Rudra, J E Bates, C Steuer, J S Remick, K Cummings, N P Joshi, N M Woody, J L Geiger, M R Patel, N C Schmitt, M W El-Deiry,G Chen, A Wieland, M Abazeed, D J Adelstein,R Ahmed, K A Higgins, J J Beitler, D M Shin,W J Curran, M W McDonald, S Koyfman

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2021）

引用 0|浏览3

暂无评分

摘要

Reirradiation with IMRT with concurrent and adjuvant nivo in patients with RSPT appears to be well tolerated with preservation of QOL measures during and following completion of therapy. Follow up for clinical efficacy measures of IMRT-nivo continues.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要